AlzeCure Pharma – Advances in the treatment of Alzheimer’s disease – Small molecule gamma-secretase modulators (GSMs) as promising disease-modifying treatments

15:00 CET / 09:00am ET

Program:

15:00  Welcome address, agenda & company overview – Martin Jönsson, CEO, AlzeCure

15:10  Alzheimer’s and amyloid hypothesis – Henrik Zetterberg¹, MD, PhD, Gothenburg Univ. & University College London

15:50  Alzstatin: a small molecule disease modifying and preventive therapy against Alzheimer’s – Johan Sandin, PhD, CSO, AlzeCure

16:05  Q&A

16:25  Concluding remarks – Martin Jönsson, CEO, AlzeCure